Email ID
Password
Scrip   
Canada wary of Xolair report concerns
14 August 2009
Becky Debens

Health Canada will conduct a safety review of Novartis/ Genentech's asthma drug Xolair (omalizumab), after initial findings from a US report linked the drug to increased cardiovascular and cerebrovascular events.
Xolair, the first approved humanised antibody treatment for asthma, is indicated...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36